Maiara C. Montanha

Av. Colombo, 5790, Zona Sete
Maringa, PR 87020900, Brazil

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach.

Optimal dosing of amoxicillin in obese and post-gastric bypass patients using a population pharmacokinetics-pharmacodynamics model approach.

Journal: The Journal of antimicrobial chemotherapy

Published: February 23, 2025

Physiologically based pharmacokinetic modeling of drug-drug interactions between ritonavir-boosted atazanavir and rifampicin in pregnancy.

Physiologically based pharmacokinetic modeling of drug-drug interactions between ritonavir-boosted atazanavir and rifampicin in pregnancy.

Journal: CPT: pharmacometrics & systems pharmacology

Published: July 17, 2024

Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin.

Pharmacokinetics and Safety of Twice-daily Ritonavir-boosted Atazanavir With Rifampicin.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: July 27, 2023

Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy.

Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy.

Journal: British journal of clinical pharmacology

Published: May 31, 2023

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling.

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling.

Journal: Frontiers in pharmacology

Published: October 21, 2022

Correction to: Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling.

Correction to: Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling.

Journal: Clinical pharmacokinetics

Published: September 16, 2022

A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human.

A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human.

Journal: Drug delivery and translational research

Published: April 27, 2022

PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease.

PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease.

Journal: Frontiers in pharmacology

Published: November 15, 2021

Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling.

Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling.

Journal: Clinical pharmacokinetics

Published: August 09, 2021

Pharmacokinetics of amoxicillin in obese and nonobese subjects.

Pharmacokinetics of amoxicillin in obese and nonobese subjects.

Journal: British journal of clinical pharmacology

Published: August 22, 2020

Physiologically-Based Pharmacokinetic Model on the Oral Drug Absorption in Roux-en-Y Gastric Bypass Bariatric Patients: Amoxicillin Tablet and Suspension.

Physiologically-Based Pharmacokinetic Model on the Oral Drug Absorption in Roux-en-Y Gastric Bypass Bariatric Patients: Amoxicillin Tablet and Suspension.

Journal: Molecular pharmaceutics

Published: November 14, 2019

Reduced bioavailability of oral amoxicillin tablets compared to suspensions in Roux-en-Y gastric bypass bariatric subjects.

Reduced bioavailability of oral amoxicillin tablets compared to suspensions in Roux-en-Y gastric bypass bariatric subjects.

Journal: British journal of clinical pharmacology

Published: January 24, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026